Foghorn Therapeutics Inc.FHTXNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank43
3Y CAGR-10.9%
5Y CAGR-64.4%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
-10.9%/yr
Annual compound
5Y CAGR
-64.4%/yr
Recent acceleration
Percentile
P43
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineCompressed
PeriodValueYoY Change
20259.72-8.7%
202410.65+54.5%
20236.89-49.9%
202213.76-97.8%
2021612.05-64.2%
20201709.19-
20190.00-
20180.00-